Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Список исп. литературыСкрыть список 1. Аведисова А.С. Особенности психофармакотерапии больных с пограничными психическими расстройствами (клинико-фармакологическое изучение действия антидепрессантов, ноотропов и гипнотиков). Дисс. ... д-ра мед. наук. М., 1999. 2. Аведисова А.С. Современные направления психофармакотерапии при пограничных психических расстройствах. Старые и новые проблемы пограничной психиатрии. М., 1997; с. 58–67. 3. Ахапкин Р.В. Объективная и субъективная оценки нежелательных явлений при изучении сравнительной переносимости антидепрессантов. Психиатрия и психофармакотер. 2003; 3. 4. Тихоненко В.А. Этика практической психиатрии. Руководство для врачей. М., 1996. 5. Гурович И.Я. Побочные эффекты и осложнения при нейролептической терапии больных шизофренией. Дисс. ... д-ра мед. наук. М., 1971. 6. Гурович И.Я., Шмуклер А.Б. Амбулаторное лечение коаксилом (динамика антидепрессивного эффекта, социального функционирования и качества жизни больных). Социальн. и клин. психиатр. 1996; 6 (3): 98–6. 7. Гурович И.Я., Шмуклер А.Б. Амизол: социальное функционирование и качество жизни в процессе лечения. Социальн. и клин. психиатр. 1996; 6 (2): 92–8. 8. Гурович И.Я., Шмуклер А.Б., Любов Е.Б. Актуальные социальные проблемы психиатрии. М., 1989. 9. Дробижев М.Ю. Нозогении (психогенные реакции) при соматических заболеваниях. Дисс. ... д-ра мед. наук. М., 2000. 10. Личко А.Е., Иванов Н.Я. Журн. невропатол. и психиатр. 1980; 8. 11. Лоуренс Д.Р., Бенитт П.Н. Побочные эффекты лекарственных веществ. Клиническая фармакология: В 2-х т. Т. 1: Пер с англ. М.: Медицина, 1991. 12. Менделевич В.Д. Посев. М., 1992. 13. Менделевич В.Д. Психиатрическая пропедевтика. М., 1997. 14. Мосолов С.Н. Клиническое применение современных антидепрессантов. СПб., 1996. 15. Мосолов С.Н. Основы психофармакотерапии. М., 1996. 16. Николаева В.В. Влияние хронической болезни на психику. М., 1987. 17. Райский В.А., Спивак Л.И., Виленский Б.С. Осложнения психофармакологической терапии. Л.: Медицина, 1988. 18. Рубенштейн С.Я. Экспериментальные методики патопсихологии. М.: Медицина, 1970. 19. Савенко Ю.С. Логос.1992; 1. 20. Смирнова Г.В. Психические расстройства у онкологических больных. Рус. мед. журн. 2000; 4. 21. Смулевич А.Б. Малопрогредиентная шизофрения и пограничные состояния. М.: Медицина, 1987. 22. Соколова Е.Т. Самосознание и самооценка при аномалиях личности. М., 1988. 23. Aguglia E, Casacchia M, Cassano G. B. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Intern Clin Psychopharmacol 1993; 8: 197–202. 24. Carey N. Do you feel powerless when a patient refuses medication? J Psychosoc Nurs Ment Health Serv 1995 Oct; 28 (10). 25. Casey DE. Striking a balance between safety and efficacy: experience with the SSRI sertraline. Int Clin Psychopharmacol 1994; 9 (3): 5–12. 26. Cassano GB, Sovino M, Musetti L et al. Serotonin-related psychiatric syndromes: Clinical and therapeutic links. London. 1991; p. 73–82. 27. Cassem N. Cardiovascular effects of antidepressants. J Clin Psychiatry 1982; 43 (11 Pt 2): 22–9. 28. Clary J, Brit J. Psychiat 1988; 153 (suppl. 3): 26–39. 29. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatric Services 1998; 49: 196–201. 30. Curran HV, Sakulsriprong M, Lader M Antidepressants and human memory: an investigation of four drugs with different sedative and anticholinergic profiles. Psychopharmacology (Berl) 1988; 95 (4): 520–7. 31. De Wilde J, Spiers R, Mertens C et al. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 1993; 87 (2): 141–5. 32. Deaumont GJ. Quality of life in primary care. J Hum Psychopharmacol 1994; 9: 25–9. 33. Demyttenaere K. Compliance during treatment with antidepressants; J Affect Disord 1997; 43. 34. Fawcett J. Compliance: definitions and key issues. J Clin Psychiatry 1995; 56 [suppl. 1]: 4–10. 35. Frank E. Enhancing patient outcomes: treatment adherence. J Clin Psychiatry 1997; 58 (suppl. 1): 11–4. 36. Geller JL. State hospital patients and their medication – do they know what they take? Am J Psychiatry 1982 may; 5. 37. Glassman AH. The newer antidepressant drugs and their cardiovascular effects. Psychopharmacol Bull 1984; 20 (2): 272–9. 38. Hollon SD, Fawcett J. Combined medication and psychotherapy. In Gabbard G, ed. Treatment of Psychiatric Disorders. Washington, DC: American Psychiatric Press 1995; 1221–36. 39. Janicak PG, Davis JM, Preskorn SH, Ayd FJ. Principles and practice of psychopharmacotherapy. Lippincott, Williams and Wilkins, 1993. 40. Kamaldeep Bhui, Shuina Hag and Geraldine Strathdee Improving treatment adherence among patients with chronic psychoses. Psychiatr Bull 1998; 22: 77–81. 41. Katon W et al. A multifaceted intervention to improve treatment of depression in primary care. Arch Gen Psychiatry 1996; 53: 924–32. 42. Kornstein SG, Schatzberg AF, Thase ME et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000; 157 (9): 1445–52. 43. Krupnick JL et al. The role of therapeutic alliance in psychotherapy and pharmacotherapy outcome: findings in the NIMH Treatment of Depression Collaborative Research Program. J Consult Clin Psychol 1996; 64: 532–9. 44. Lin K. Psychiatric Clinics of North America. Ethnicity psychofarmacol 1995; 18: 635–47. 45. Macleod MS, Sharp DM. Precursors of compliance with lithium treatment in affective disorders. Psychiat Bull 2001; 25: 183–6. 46.Marder SR, Swann E, Winslade WJ, Van Putten T. A study of medication refusal by involuntary psychiatric patients; Hosp Community Psychiatry 1984 Jul; 35 (7). 47. McEvoy R. Cognitive perfomance enhancing effects of the reversible MAO-inhibitor moclobemide in animals. In: Alzheimer Disease, eduted by R.J. Wurtman et al., Cambrige, MA, 1988; p. 689–94. 48. Merccier C. The role of subjective factors in medication compliance; Can J Psychiatry 1989; 34: 49. Meredith LS et al. Counseling typically provided for depression: role of clinician specialty and payment system. Arch Gen Psychiatry 1996; 53: 905–12. 50. Montgomery SA, Kasper S. Comparison of Compliance between Serotonin Reuptake Inhibitors and Tricyclic Antidepressants: A Meta-Analysis. International Clinical Psychopharmacology. 1995; 9 (suppl. 4): 33–40. 51. Montgomery SA. Brit J Psychat 1988; 153 (suppl. 3): 7–10. 52. Montgomery SA, Roberts A, Montgomery DB. Depression: A long-term illness symposium in Washington, D.C. J. Mendlewicz, A. Classman (Eds.); Lundbeck, 1994; p. 57–63. 53. Nierenberg AA. Treatment- resistant depression: definition and treatment approaches J Clin Psychiatry 1990; 6. 54. Nierenberg AA. Current perspectives on the diagnosis and treatment of major depressive disorder. Am J Manag Care 2001 Sep; 7 (11 Suppl.): S353–66. 55. Olfson M, Mechanic D, Hansell S. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000 Feb; 2. 56. Parker D, Tennant Ch, Blegnault I. Predicting Improvement in Patients with non-endogenous depression. Brit J Psychiatry 1985; 146 (2): 132–9. 57. Paykel ES. Depression in medical in-patients. Brit J Psychiatry 1995; 126. 58. Perry C. A problem with refusing certain forms of psychiatric treatment. Soc Sci Med 1985; 20 (6). 59. Prehn RA Medication refusal: suggestions for intervention. Psychiatr Hosp 1990; 21 (1). 60. Quitkin FM, Gittelman-Klein R, Rifkin A, Klein DF. Atypical signs of relapse in affective disorders. Ann Pharmacother 2003 Apr; 37 (4): 543–5. 61. Ray WA, Griffin MR, Schaffner W et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987; 316: 363–9. 62. Roberis H. Neurotic patients who terminate their own treatment. Br J Psychiatry 1985; 146 (4): 443–5. 63. Robinson D, Barker E. Tricyclic antidepressant cardiotoxicity. JAMA 1976; 236 (18): 2089–90. 64. Saechetti E, Vital A, Guarneri L et al. Serotonin-related psychiatric syndromes: Clinical and Therapeutic Links. London, 1991; p. 47–54. 65. Salzman C. Medication compliance in the elderly. J Clin Psychiatry 1995; 56 [suppl. 1]: 18–22. 66. Schwartz P, Wolf S. QT interval prolongation as predictor of sudden death in patients with myocardial infarction. Circulation 1978; 57 (6): 1074–7. 67. Shawcross CR, Tyrer P. Influence of personality on response to monoamine oxidase inhibitors and tricyclic antidepressants. J Psychiat Res 1985; 19 (4): 557–62. 68. Souery D, Mendlewicz J. Compliance and therapeutical issues in resistant depression. Am J Psychiatry 1997 jul; 7. 69. Sperry L. Psychopharmacology and Psychotherapy: Strategies for Maximizing Treatment Outcomes. New York, Brunner/Mazel, 1995; p. 50–1. 70. Stokes PE. Review of comparative clinical trials: moclobemide vs other antidepressants and vs placebo in depressive states. Psychopharmacology 1988; 96: 325. 71. Psychiatr J Univ Ott. 1989 Jun;14(2):367–9; discussion 370–1. 72. Urrita G. Medication refusal – clinical picture and outcome after use of administrative review. Bull Am Acad Psychiatry Law 1994; 22: 595–603. 73. Ward N. Psychosocial approaches to pharmacotherapy. In Beitman B, Klerman G, eds. Integrating pharmacotherapy and psychotherapy. Washington, DC: American Psychiatric Press, 1991; p. 69–104. 74. Weiss M, Gaston L, Propst A et al. The role of the alliance in the pharmacologic treatment of depression. J Clin Psychiatry 1997; 58: 186–204. 75. Worthington J, Fava M, Agustin C et al. Consumption of alcohol, nicotine, and caffeine among depressed outpatients: relationship with response to treatment. Psychosomatics 1996; 37: 518–22. 76. Zito JM, Routt WW, Mitchell JE, Roerig JL. Clinical characteristics of hospitalized psychotic patients who refuse antipsychotic drug therapy. Am J Psychiatry 1985 jul; 7: 822–6.